You are here

Article Text

Article menu
Download PDFPDF
BJO at a glance
BJO at a glance
  1. Creig Hoyt, Editor

    https://doi.org/10.1136/bjo.2005.bjjun05at%20a%20glance

    Statistics from Altmetric.com

      Request Permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

      SIROLIMUS TREATMENT FOR UVEITIS

      Sirolimus was originally developed as an antibiotic. Its potential as an immunomodulatory agent has been established for the prevention of allograft rejection following solid organ transplantation. Shanmuganathan and co-workers report the use of sirolimus in eight patients with severe non-infectious uveitis. It appeared to be an effective and potent immunosuppressant treatment in these patients. See p 666

      DECREASED ANTIOXIDANT STATUS IN DIABETIC RETINOPATHY

      The formation and accumulation of advanced glycation end products (AGE) is known to progress during normal aging and is extremely accelerated in diabetes mellitus. Yokoi and co-workers report that in the vitreous of patients with diabetic retinopathy there are increased levels of advanced glycation end products. The vitreous levels of AGE and VEGF (vascular growth factor) …

      View Full Text

      Linked Articles